{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Intraocular drug delivery is a promising approach for treatment of ocular diseases."
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Treatment of etoposide\u2010resistant RB cells with ANP\u2010HA\u2010GNPs in\u2009ovo resulted in significantly reduced tumor growth and angiogenesis compared with controls."
      },
      "Objective": {
        "score": 1,
        "evidence": "Therefore, new adjuvant therapies are needed to treat chemoresistant RBs."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Treatment of etoposide\u2010resistant RB cells with ANP\u2010HA\u2010GNPs in\u2009ovo resulted in significantly reduced tumor growth and angiogenesis compared with controls."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Treatment of etoposide\u2010resistant RB cells with ANP\u2010HA\u2010GNPs in\u2009ovo resulted in significantly reduced tumor growth and angiogenesis compared with controls."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 6,
    "max_score": 25
  },
  "model": "gpt-4o"
}